nutch_noindex
CANCEL
COVID-2019 Alert

Information about the 2019 Novel Coronavirus. Read the latest >

Información sobre el coronavirus 2019 (COVID-19). Aprenda más >

/nutch_noindex

Elizabeth Profita, MD

  • Elizabeth Loudon Profita

Specialties

Cardiology

Work and Education

Professional Education

University of Washington School of Medicine, Seattle, WA, 6/4/2011

Residency

Boston Childrens Hospital Pediatric Residency, Boston, MA, 6/30/2014

Fellowship

Boston Childrens Hospital Heart Failure and Transplant Fellowship, Boston, MA, 6/30/2018

Boston Childrens Hospital Pediatric Cardiology Fellowship, Boston, MA, 6/30/2017

Board Certifications

Pediatric Cardiology, American Board of Pediatrics

Pediatrics, American Board of Pediatrics

All Publications

Incidence, predictors, and outcomes after severe primary graft dysfunction in pediatric heart transplant recipients JOURNAL OF HEART AND LUNG TRANSPLANTATION Profita, E. L., Gauvreau, K., Rycus, P., Thiagarajan, R., Singh, T. P. 2019; 38 (6): 6018
Extracorporeal membrane oxygenation use in the first 24hours following pediatric heart transplantation: Incidence, risk factors, and outcomes. Pediatric transplantation Godown, J., Bearl, D. W., Thurm, C., Hall, M., Feingold, B., Soslow, J. H., Mettler, B. A., Smith, A. H., Profita, E. L., Singh, T. P., Dodd, D. A. 2019: e13414

Abstract

Primary graft dysfunction following HTx is associated with significant morbidity and mortality. This study aimed to assess the incidence of, risk factors for, and outcomes of children requiring ECMO within 24hours of HTx. This study utilized a linked PHIS/SRTR database of pediatric HTx recipients (2002-2016). Post-HTx ECMO was identified using inpatient billing data. Logistic regression assessed risk factors for post-HTx ECMO. Kaplan-Meier analyses assessed in-hospital mortality and post-discharge survival. A total of 2820 patients were included with 224 (7.9%) requiring ECMO. Independent risk factors for post-HTx ECMO include age <1year (aOR: 2.2, 95% CI: 1.3-3.7, P=0.006) or 1-5years (aOR: 2.1, 95% CI: 1.3-3.4, P=0.002), and ECMO support at HTx (aOR: 27.4, 95% CI: 15.2-49.6, P<0.001). Survival to discharge decreased with increasing duration of post-HTx ECMO support; 89% for 1-3days, 79.1% for 4-6days, 63.2% for 7-9days, and 18.8% for 10days. There was no difference in long-term survival for patients requiring post-HTx ECMO who survived to hospital discharge (P=0.434). There are identifiable risk factors associated with the need for ECMO in the post-HTx period. Length of time on ECMO post-HTx is strongly associated with the risk of in-hospital mortality. Patients who require ECMO early post-HTx and survive to discharge have comparable outcomes to patients who did not require ECMO.

View details for PubMedID 30973190